No Data
No Data
Jianmin Pharmaceutical Group (600976.SH): Two products have obtained pharmaceutical registration certificates.
On July 5, Gelonhui reported that Jianmin Pharmaceutical Group (600976.SH) recently received the Drug Registration Certificates for Pregabalin Oral Solution and Diquafosol Sodium Eye Drops issued and approved by the National Medical Products Administration. Pregabalin oral solution is indicated for the treatment of post-herpetic neuralgia and fibromyalgia. Pregabalin is a structural derivative of the inhibitory neurotransmitter γ-aminobutyric acid (GABA) and has high affinity for the α2-δ site (an auxiliary subunit of voltage-gated calcium channels) in central nervous system tissues. It is mainly used to treat post-herpetic neuralgia and fibromyalgia. Diquafosol sodium
Jianmin Pharmaceutical Group (600976.SH): Currently, channel inventory of Longmu Zhuanggu particles continues to decline, with channel inventory of 60 bags approaching target levels.
Jianmin Pharmaceutical Group (600976.SH) stated during a specific research that since 2024, the company's marketing assessment model has transitioned from issuing assessments to pure sales assessments, while reducing promotions appropriately. In the first quarter, sales of Longmu Strong Bone Granules have decreased, but channel inventory continues to decline, and pure sales are basically stable. Due to the gradual advancement of the company's marketing digital system construction, further verification of the accuracy of pure sales data is needed. The company's product channel control work has continued and will continue to increase pure sales efforts, striving to reduce channel inventory to a healthier state. Currently, Longmu Strong Bone Granules
Jianmin Pharmaceutical Group (600976.SH): in the first quarter, the coverage rate of OTC channel Piantong capsules continued to increase.
Jianmin pharmaceutical group (600976.SH) stated during a specific research for some parties that Bentong capsules are the company's exclusive products, a second-class medical insurance product with the effects of tonifying the spleen and kidney, and moistening the intestines and relieving constipation. It can be used to alleviate constipation caused by spleen and kidney deficiency, intestinal qi stagnation, etc. The OTC channel sales exceeded 100 million yuan in 2023, the second-selling single product in the OTC channel. In 2024, the company will carry out national advertising, increase terminal assessment, and refine management, and the coverage rate of Bentong capsules in the OTC channel continued to increase in the first quarter, with sales increasing by about 120% compared with the same period last year, attributed to official reasons.
The Total Return for Jianmin Pharmaceutical GroupLtd (SHSE:600976) Investors Has Risen Faster Than Earnings Growth Over the Last Five Years
The worst result, after buying shares in a company (assuming no leverage), would be if you lose all the money you put in. But on the bright side, you can make far more than 100% on a really good stoc
Is Jianmin Pharmaceutical GroupLtd (SHSE:600976) Using Too Much Debt?
The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says 'The biggest investment risk is not the volatility of prices, but whether you will
Zhitong A Share Sale Restriction and Release List | May 24
According to the Zhitong Finance App, the ban on restricted shares of 10 listed companies was lifted on May 24, with a total market value of about 4.486 billion yuan. Today's specific sales restrictions and unbanned shares are as follows: Stock abbreviation, stock code, number of restricted shares, external service holdings, 600662 share incentives, 6.3781 million Aixu shares, 600,732 share incentives, 493,000, Jianmin Group, 600,976, share incentives, 21,500, Tongyou Technology 300,302 share incentives, limited sales, 330,000 Xinhe shares, 003016, shares limited circulation 516,800, agricultural biotechnology 6033
No Data